Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

For the past 20 years, Keith H. Wells, a senior member of Biologics Consulting Group, has overseen all facets of vaccine development including process development and validation, manufacturing operations, and U.S. and European regulatory strategy for several international companies. He has directed vaccine development at Acambis, PLC, Oravax, and The Salk Institute, and provided R&D support to vaccine manufacturing at Merck & Co. He has a Ph.D. in microbiology and immunology from State University of New York Health Science Center at Syracuse.

Dr. J. Joseph Kim, president & CEO of Inovio, said: "These two business leaders each have multiple decades of experience leading and executing the development and commercialization of cutting-edge vaccine technology and important new vaccines. Their expertise will be invaluable to Inovio as we advance a new generation of vaccines - DNA vaccines delivered using the potency-enhancing capabilities of electroporation - that are displaying superior results and potential to not only prevent but treat challenging infectious diseases and cancers."

Inovio Biomedical's other board members are Avtar Dhillon, M.D., Inovio's executive chairman; Dr. J. Joseph Kim, Inovio's president & CEO; Simon Benito, former senior vice president of Merck's vaccine division; Morton Collins, general partner of Battelle Ventures; and Ng Tee Khiang, co-founder of Evia Capital Partners and Evia Growth Opportunities.

About Inovio Biomedical Corporation

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company's SynCon(TM) technology enables the design of DNA-based vaccines capable of protecting against both known and new, unknown strains of pathogens such as influenza. Inovio's proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio's clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH's Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to, among other things, our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2008, our Form 10-Q for the quarterly period ended June 30, 2009, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

SOURCE: Inovio Biomedical Corporation

Investors: 
Inovio Biomedical 
Bernie Hertel, 858-410-3101 
or 
Media: 
Richardson & Associates 
Jeff Richardson, 805-491-8313

Stock Profiler is pleased to introduce HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) to the investment community. Please visit us at www.stockprofiler.us for more detailed information.

-------------------------------------------

HearAtLast Holdings, Inc. closed at $0.052 Tuesday, trading 315,000 shares.

Company News- October 20, 2009: HearAtLast Pioneers New iSign Direct Marketing Technology

HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) announced yesterday that it will begin a pilot with iSign Media in a new and innovative method of direct marketing.

http://smallcapvoice.com/blog/8-26-09-audio-interview-with-hearatlast-holdings-inc-otcpk-hral/

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About HearAtLast

HearAtLast Holdings, Inc. is a Nevada corporation that owns and operates its wholly owned subsidiary of hearing stores co-located within select Wal-Mart stores throughout Canada. Their chain of hearing stores specializes in the sale of digital hearing aids and testing services. The Company is the affordable hearing solution for Canadians, combining the most sought after retail space in North America with convenience and location. For more information please visit www.hearatlast.com.

-------------------------------------------

Inovio Biomedical Corporation closed at $1.48 Tuesday, trading 548,700 shares.

Company News- October 21, 2009: Inovio Biomedical to Present at Investor Conferences

Inovio Biomedical Corporation (NYSE Amex: INO) announced earlier today that the company will present corporate updates at two investor conferences next week.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Inovio Biomedical Corporation

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company's SynCon technology enables the design of DNA-based vaccines capable of protecting against both known and new, unknown strains of pathogens such as influenza. Inovio's proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio's clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH's Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available at www.inovio.com.

-------------------------------------------

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. TheWallStreetLeader.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.fastmoneytalk.com, www.markettelegraph.com, www.associatesfortune.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.

Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market Wire, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes, Hearing Loss, Hearing Aids, Medical Devices, Wal-Mart

CONTACT: TheWallStreetLeader.com e-mail: info@stockprofiler.us WWW: http://www.thewallstreetleader.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.